TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03563040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxsalen
Description: Methoxsalen is used in conjunction with the THERAKOS CELLEX Photopheresis System.~During each photopheresis treatment with methoxsalen, the dosage of methoxsalen is calculated according to the treatment volume (which is displayed on the display panel of the instrument) using the formula:~Treatment volume x 0.017 ml of methoxsalen (20 µg/mL) for each treatment For example: Treatment volume = 240 mL x 0.017 = 4.1 mL of methoxsalen (20 µg/mL)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THERAKOS CELLEX Photopheresis System
Description: Methoxsalen is used in conjunction with the THERAKOS CELLEX Photopheresis System.
Study: NCT03384446

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tooth-borne treatment
Description: Titanium curettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implant-specific treatment
Description: Implant brush
Study: NCT01310413

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A (H5N1) Virus monovalent vaccine
Description: All subjects will receive 2 doses administered as an intramuscular (IM) injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A (H5N1) Virus monovalent vaccine
Description: All subjects will receive 2 doses administered as an intramuscular (IM) injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A (H5N1) Virus monovalent vaccine
Description: All subjects will receive 2 doses administered as an intramuscular (IM) injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A (H5N1) Virus monovalent vaccine
Description: All subjects will receive 2 doses administered as an intramuscular (IM) injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: All subjects will receive 2 doses administered as an intramuscular (IM) injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: All subjects will receive 2 doses administered as an intramuscular (IM) injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: All subjects will receive 2 doses administered as an intramuscular (IM) injection.
Study: NCT04571164

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo,extended-release microspheres
Description: During the intervention,the initial does was 14mg,and then was incremented in weekly units,14mg each time,until the maximum does of 56mg set in this study was reached 4 weeks after titration,the optimal therapeutic does or the maximum tolerated does was entered into the dosing maintenance period.After entering the maintenance period,no does adjustment was performed,and the stable does was maintained for 24 weeks.
Study: NCT03001427

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured center-based lifestyle intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard education and physician advice
Study: NCT01906931

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable oxygen concentrator
Description: Respironics EverGo portable oxygen concentrator on setting 6
Study: NCT03724604

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuron-Specific Enolase to Albumin Ratio
Description: Previous studies have shown that inflammation and nutrition-related factors such as CRP/Alb (C-reactive protein-albumin ratio), PLR (platelet-to-lymphocyte ratio), NLR (neutrophil-to-lymphocyte ratio) can help to assess the prognosis of malignant tumors. This study is the first time to combine NSCLC tumor marker NSE and patient nutrition-related indicators Alb to predict the prognosis of patients, trying to find high sensitivity and specificity for NSCLC prognostic indicators to guide clinical work.

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuron-Specific Enolase to Albumin Ratio
Description: Previous studies have shown that inflammation and nutrition-related factors such as CRP/Alb (C-reactive protein-albumin ratio), PLR (platelet-to-lymphocyte ratio), NLR (neutrophil-to-lymphocyte ratio) can help to assess the prognosis of malignant tumors. This study is the first time to combine NSCLC tumor marker NSE and patient nutrition-related indicators Alb to predict the prognosis of patients, trying to find high sensitivity and specificity for NSCLC prognostic indicators to guide clinical work.
Study: NCT03405467

Intervention type: OTHER
Intervention: general and specific data
Description: General and specific data collected

Intervention type: OTHER
Intervention: general and specific data
Description: General and specific data collected
Study: NCT01906931

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Portable oxygen concentrator
Description: Respironics EverGo portable oxygen concentrator on setting 6
Study: NCT00678600

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard (static) Computer Alerts
Description: Static Computer Alerts on Patient's EMR webpage.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Computer Alerts
Description: Population level and asynchronous alerts with enhanced functionality
Study: NCT04448860

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: performance of behavioral locomotion tasks phase 1
Description: The performance of behavioral locomotion tasks is performed on 4 visits on pilot phase (2 in real condition and 2 in virtual reality in D1 and M1)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: performance of behavioral locomotion tasks phase 2
Description: The performance of behavioral locomotion tasks is performed on 6 visits on validation phase (3 in real condition and 2 in virtual reality in D1, M1 and M12)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: performance of behavioral locomotion tasks phase 2
Description: The performance of behavioral locomotion tasks is performed on 6 visits on validation phase (3 in real condition and 2 in virtual reality in D1, M1 and M12)
Study: NCT05252026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROCARE-I (UP-A for indicated purposes)
Description: This intervention is meant to respond to the heterogeneity inherent in emotional difficulties presentation by extinguishing distress associated with the presentation of heightened negative emotion in general and reduction or elimination of resultant emotionally-driven behaviours, including avoidance, escape, aggression, and controlling behaviours (e.g., reassurance seeking) that reinforce emotional distress intensity over time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active control condition
Description: Psychoeducation about many different emotions, emphasis on discussing thoughts, feelings, and behavior as parts of emotion, and emphasis on providing support around generally distressing events.
Study: NCT01643473

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence Intervention
Description: Patients randomized to the TAI group will complete a tailoring survey at the baseline visit to identify the most salient adherence barriers to the individual, which will be used to create an individualized adherence profile. Following completion of the tailoring survey, patients will collaborate with the RA to identify the most suitable mix of intervention strategies for improving medication adherence (i.e., reminder aids, motivational interviewing, case management) that are matched to the barriers outlined on patients' individualized adherence profiles.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Health education videos on topics unrelated to medication adherence, hypertension or type 2 diabetes
Study: NCT03205085

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: assessment of right heart dimensions and function by cardiac magnetic resonance Imaging.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: assessment of right heart dimensions and function by cardiac magnetic resonance Imaging.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2D and 3D trans-thoracic echocardiography
Description: assessment of right heart dimensions and function by 2D and 3D trans-thoracic echocardiography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2D and 3D trans-thoracic echocardiography
Description: assessment of right heart dimensions and function by 2D and 3D trans-thoracic echocardiography

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Blood samples for assays of immune inflammatory biomarkers (InterLeukin-18, CXCL9 or interferon

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Blood samples for assays of immune inflammatory biomarkers (InterLeukin-18, CXCL9 or interferon
Study: NCT00569972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0200390
Description: Capsules, 45 mg, 3 capsules each night before bedtime, Duration- Visit 3-7 for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0200390
Description: Capsules, 60 mg, 3 capsules each night before bedtime, Duration - Visit 3-7 for 28 days
Study: NCT03603886

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine Pain Management Intervention (immediate group)
Description: Four weekly telemedicine pain management sessions with a trained provider. Intervention will be delivered via video conferencing platform, and each session will last between 30 and 45 minutes. Intervention topics will include: pain psychoeducation, pain coping tools, pain communication, and pain-related stress management.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telemedicine Pain Management Intervention (waitlist group, intervention administered following 4-week waitlist period)
Description: Four week waitlist period during which participants receive treatment as usual. Following the waitlist period, participants will receive the telemedicine pain management intervention:~Four weekly telemedicine pain management sessions with a trained provider. Intervention will be delivered via video conferencing platform, and each session will last between 30 and 45 minutes. Intervention topics will include: pain psychoeducation, pain coping tools, pain communication, and pain-related stress management.
Study: NCT00585949

Intervention type: PROCEDURE
Intervention: Percutaneous Coronary Angioplasty
Description: This is a procedure by which the blood vessels of the heart are imaged with an insertion of a catheter in the groin and blocked arteries are opened.

Intervention type: PROCEDURE
Intervention: Angiography
Description: Angiography is an imaging technique to see coronary blood vessels.
Study: NCT01906931

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable oxygen cylinder
Description: Portable oxygen cylinder at flow rate 5 Litres/min

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Portable oxygen cylinder
Description: Portable oxygen cylinder at flow rate 5 Litres/min
Study: NCT01112995

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus
Description: 1 pill formulation to be given once a day for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill (placebo)
Description: placebo identical to the active product will be given
Study: NCT02453594

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV infusion
Study: NCT00569972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched oral placebo for weeks 2-7.
Study: NCT02329015

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga-informed Health and Wellness Program
Description: The HWP will be comprised of physical postures, breathing exercises, a period of sitting in stillness (meditation) and relaxation provided two times per week, 45 minutes per session, for the entire school year (Sept. - June).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Education Class
Description: Standard physical education
Study: NCT05727358

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based Acceptance and Commitment Therapy
Description: G-ACT treatment in this study comprised 7 sessions of 45-60 minutes and was administered throughout the course of the 4-week long trial.
Study: NCT04186962

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral: Simple cognitive task
Description: A memory reactivation cue followed by playing the computer game Tetris
Study: NCT01532362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apricoxib
Description: As part of the trial, forty eligible subjects will be randomly assigned to receive Apricoxib 400 mg orally once daily or no drug intervention for a 7 day period (Days 0-6) prior to surgical resection of the lung tumor but between the two surgeries.

Intervention type: DRUG
Group type: OTHER
Intervention: Apricoxib
Description: As part of the trial, forty eligible subjects will be randomly assigned to receive Apricoxib 400 mg orally once daily or no drug intervention for a 7 day period (Days 0-6) prior to surgical resection of the lung tumor but between the two surgeries.
Study: NCT01383681

Intervention type: OTHER
Intervention: No treatment
Description: There was no treatment in this study.
Study: NCT01323569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: Sativex dose level 1: 10.8 mg THC/10 mg CBD (4 sprays) + 12 placebo sprays + 4 placebo capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: Sativex dose level 2: 21.6 mg THC/20 mg CBD (8 sprays) + 8 placebo sprays + 4 placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: Sativex dose level 3: 43.2 mg THC/40 mg CBD (16 sprays) + 4 placebo capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 16 placebo sprays and 4 placebo capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marinol
Description: Marinol dose level 1: 20 mg THC (2 marinol capsules) + 2 placebo capsules + 16 placebo sprays

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marinol
Description: Marinol dose level 2: 40 mg THC (4 marinol capsules) + 16 placebo sprays
Study: NCT00634647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satraplatin
Description: 80 mg/m\^2 days 1-5 of every 35 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 5 mg twice daily every 35 days
Study: NCT03747484

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interferon Gamma-1b
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interferon Gamma-1b
Description: Given SC
Study: NCT02309385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8% Dexamethasone Sodium Phosphate - Visulex

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15% Dexamethasone Sodium Phosphate - Visulex
Study: NCT04121169

Intervention type: DRUG
Group type: OTHER
Intervention: IM-01
Description: Antibodies react with C. difficile toxin, C. difficile bacteria and spores; neutralizes the toxin and inhibit the growth of spores and vegetative forms of C. difficile

Intervention type: DRUG
Group type: OTHER
Intervention: IM-01
Description: Antibodies react with C. difficile toxin, C. difficile bacteria and spores; neutralizes the toxin and inhibit the growth of spores and vegetative forms of C. difficile
Study: NCT02309385

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone Acetate (1%) Eye Drops
Study: NCT04281277

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: increase of mean arterial pressure at 80-85 mmHg.
Description: increase of mean arterial pressure at 80-85 mmHg (with catecholamines or volemic expansion).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: increase of mean arterial pressure at 65-70 mmHg.
Description: increase of mean arterial pressure at 65-70 mmHg (with catecholamines or volemic expansion).
Study: NCT02212730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Pre-Resection
Description: 200 mg administered by IV, once every 3-week cycle for a maximum of 2 cycles

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Standard of care surgical resection of RCC tumor

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Standard of care surgical resection of RCC tumor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Post-Resection
Description: 200 mg administered by IV, once every 3-week cycle for a maximum of 17 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Post-Resection
Description: 200 mg administered by IV, once every 3-week cycle for a maximum of 17 cycles
Study: NCT04031885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Administered IM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Chemotherapy
Description: Standard chemotherapy of physician's choice administered according to product label.
Study: NCT02621983

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: Subjects with a diagnosis of SCZ will complete aerobic exercises consisting of spin classes 3 times a week on a stationary bicycle ergometer. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Balance and Stretching
Description: Subjects with a diagnosis of SCZ will complete a balance and stretching program consisting of progressive whole body stretching and toning exercises. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
Study: NCT02366481

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo softgel capsules (containing no vitamin K2) every day for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low-Dose Vitamin K2 Supplement (menaquinone-7; 90-mcg/d)
Description: One 90-mcg vitamin K2 softgel capsules (containing no vitamin K2) and one placebo softgel capsule everyday for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High-Dose Vitamin K2 Supplement (menaquinone-7; 180-mcg/d)
Description: Two 90-mcg vitamin K2 softgel capsules every day for 8 weeks.
Study: NCT00587587

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apligraf
Description: Application at Day 0, potential re-application at Week 4

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard dressing regimen
Description: A primary nonadherent dressing, dry gauze dressing and bolster gauze dressing if necessary
Study: NCT01162005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: dosage : 0.1-0.2 mg/kg/day divided two target trough level : 5 - 10 ng/mL Total duration (tacrolimus) : 1 year
Study: NCT00854087

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fuzheng Huayu
Description: The subjects will be taking 2 tablets three times a day for 48 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subjects will be taking 2 tablets three times a day for 48 weeks.
Study: NCT02879097

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CBT124
Description: Induction Phase: CBT124 15 mg/kg IV infusion-Day 1 of each 3-week Cycle for 6 cycles; Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles; Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles. Maintenance Phase: All the subjects who complete the induction phase and are alive at Week 19 without progression of the disease can be included in the maintenance phase and receive CBT124 (bevacizumab, 15 mg/kg, intravenous infusion on Day 1 of each 3-week Cycle) up to disease progression or unacceptable toxicity (that precludes further treatment with bevacizumab) or death.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU-sourced Avastin®
Description: Induction Phase: EU-sourced Avastin® 15 mg/kg IV infusion-Day 1 of each 3-week Cycle for 6 cycles; Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles; Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles. Maintenance Phase: All the subjects who complete the induction phase and are alive at Week 19 without progression of the disease can be included in the maintenance phase and receive CBT124 (bevacizumab, 15 mg/kg, intravenous infusion on Day 1 of each 3-week Cycle) up to disease progression or unacceptable toxicity (that precludes further treatment with bevacizumab) or death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Induction Phase: Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Induction Phase: Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Induction Phase: Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Induction Phase: Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles.
Study: NCT00111644

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Description: 1000mg iv daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beta-lactam
Description: 750mg iv q 23h for 3-14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beta-lactam
Description: 1500mg iv q 12h for 3-14 days